Soft tissue sarcoma

11 trials 8 recruiting MedDRA PT
11 Registered trials
8 Recruiting
10 Unique sponsors
9 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
L Oncology (ATC L) 4
B Haematology (ATC B) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Alkylating agent 2 substances
Anthracycline 1 substance
Supportive / diluent 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Phase III: 3 Phase II: 3 Phase I/II: 1 Phase I: 3 Phase I (First in Human): 1

Filter these 11 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 11 trials

Phase III

3 trials
  • Philogen S.p.A. Commercial
    DOXORUBICIN HYDROCHLORIDE; ONFEKAFUSP ALFA
    2024-512789-32-00 5 countries 2017 n=118 Orphan
    Ended
  • Institut Gustave Roussy Academic
    SODIUM CHLORIDE; TISLELIZUMAB
    2023-503316-33-00 1 country 2024 n=717
    Recruiting
  • Unicancer Academic
    IMP not specified
    2024-510653-10-00 1 country 2021 n=214
    Recruiting

Phase II

3 trials
  • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. Academic
    ALDESLEUKIN; AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELLS
    2023-510251-31-00 1 country 2019 n=30
    Recruiting
  • Oslo University Hospital HF Academic
    DOXORUBICIN HYDROCHLORIDE; IFOSFAMIDE
    2023-510185-27-00 1 country 2021 n=50
    Recruiting
  • Philogen S.p.A. Academic
    DACARBAZINE; ONFEKAFUSP ALFA
    2024-512704-20-00 5 countries 2020 n=98 Orphan
    Ended

Phase I/II

1 trial
  • Centre Leon Berard Academic
    IMP not specified
    2024-510706-86-00 1 country 2022 n=58
    Recruiting

Phase I

3 trials
  • Merck Healthcare KGaA Commercial
    IMP not specified
    2024-513687-26-00 2 countries 2025 n=26
    Recruiting
  • Novartis Pharma AG Commercial
    IMP not specified
    2025-521702-18-00 5 countries 2026 n=62
    Recruiting
  • Incyte Corp. Academic
    IMP not specified
    2023-504400-29-00 1 country 2022 n=9
    Ended

Phase I (First in Human)

1 trial
  • Salubris Biotherapeutics Inc. Commercial
    JK06
    2024-512421-92-00 2 countries 2025 n=305
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Philogen S.p.A. Commercial 2 Phase III, Phase II 0
Merck Healthcare KGaA Commercial 1 Phase I 1
Novartis Pharma AG Commercial 1 Phase I 1
Salubris Biotherapeutics Inc. Commercial 1 Phase I (First in Human) 1
Incyte Corp. Academic 1 Phase I 0
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. Academic 1 Phase II 1
Oslo University Hospital HF Academic 1 Phase II 1
Institut Gustave Roussy Academic 1 Phase III 1
Unicancer Academic 1 Phase III 1
Centre Leon Berard Academic 1 Phase I/II 1
New trials by year
2019
1
2020
1
2021
2
2022
2
2024
1
2025
2
2026
1
← All indication landscapes